This negative regulator, FH, was chosen because alternative pathway-associated disorders, such as AMD, aHUS, C3GN, DDD, implicate FH impairment at the levels of lower effective concentration or altered binding kinetic parameters leading to improper regulation. Here, FH is linked to age-related macular degeneration.